Magnetic particles were synthesized with an iron-containing coating. The model drugs were safranin O and hydrocortisone. The particles were functionalized with a bulky azo derivative to act as a gatekeeper and stop early leakage of the drug. In vitro release models have demonstrated that most of the drug is released only in the colon, as desired. This is owing to the reductive environment in the colon (the presence of the azoreductase enzyme), where the enzymatic degradation of the azo bond resulted in controlled release. In addition, in vivo pharmacokinetic studies were conducted in a rat model of induced colitis to test the effect of the magnetic field during therapy. The findings boosted when the rats wore a magnetic belt, which extended the retention time of the particles in the desired areas [ 75 ]. Zhang et al. presented a study in which magnetic silica nanoparticles (filled with sulforaphane) were developed for the treatment of myocardial infarction [ 38 ]. In mouse models, effective accumulation was observed in the infarcted zone after the application of an external magnetic field [ 33, 75 ]. These results show the potential of using magnetic particles with magnetic field guidance [ 33 ]. Radhakrishnan et al. developed a drug delivery system (DDS) loaded with carboplatin for targeted lung cancer therapy [ 63 ]. The DDS was core-shell mesoporous silica functionalized with folic acid. Initially, the drug loading capability of the functionalized carrier was more than twice as high per surface unit compared to the non-functionalized carrier due to the anchored -NH 2 groups. The drug release was sustained but limited (up to 36%) in the case of the functionalized particle, similarly to previous cases. This is most likely owing to the stronger interactions between the amine groups and the carboplatin. The amino-functionalized particles were further functionalized with folic acid to increase cellular uptake of the particles, demonstrating the potential of folic acid-targeted therapy [ 63, 65, 76 ]. Cancer cells typically overexpress folate receptors, resulting in folate-mediated internalization that preferentially targets these cells [ 63, 76 ]. This was demonstrated in a drug-mediated cytotoxicity analysis where amino- and folate-functionalized particles were evaluated and compared. Much greater cytotoxicity was observed in cells overexpressing folate receptors [ 63 ]. Similar research was carried out by Shirani et al., where folic acid functionalized MSNs were loaded with gemcitabine as a model drug, to investigate its potential in cancer treatment, while actively targeting cancer cells [ 70 ]. Outcomes have shown that higher cellular uptake (HeLa and K562 cells) was observed in the case of the functionalized particles, compared with the non-functionalized carriers [ 70 ]. Jafarpour et al. demonstrated the importance of functionalizing the carriers to accomplish targeted therapy utilizing methotrexate as a model drug [ 76 ]. The particles were grafted with a copolymer to act as a pH-responsive gatekeeper and folic acid to actively target cancer cells [ 76 ]. Ortiz et al. similarly designed a pH-responsive DDS, loaded with the anticancer drug doxorubicin [ 11 ]. The particles were functionalized with transferrin through a pH-sensitive linker as a gatekeeper, controlling the release kinetics and preventing early leakage of the drug [ 11 ]. An interesting breast cancer therapy was published by Mal et al. using doxorubicin as API and mesoporous silica as a carrier [ 65 ]. The amine-functionalized MSNs were PEGylated and then conjugated with folic acid or hyaluronic acid. It was also published that coating the nanoparticles with polydopamine (PDA) and polyethylene glycol (PEG) brings about prolonged doxorubicin release from MSNs [ 77 ]. These conjugates enabled ligand-mediated targeted drug delivery [ 65 ]. Researchers have developed a successful DDS that targets cancer cells, thus staying away from the side effects associated with doxorubicin in conventional cancer therapy. This is important because in vitro cytotoxicity studies have shown that the free drug has higher cytotoxicity than the nanocarriers [ 65 ]. Shahbaz et al. developed a redox-responsive silica nanocarrier loaded with paclitaxel to target breast cancer cells [ 67 ]. The amine-functionalized silica core was coated with disulfide-functionalized non-porous silica shell. Then the core-shell carriers were further coated with polyethylene glycol via disulfide linkages. In vitro drug release assay verified the correlation between the redox potential of the environment and the release kinetics. This is an important finding, as it has been revealed that cancer cells possess a higher redox ability than healthy cells. This provides controlled paclitaxel release for targeted therapy. According to cell uptake and cell viability assays, this DDS is noticeably more effective than free paclitaxel, making this nanocarrier an exciting prospect [ 67 ]. These illustrations highlight the importance of surface functionalization and employing stimuli-responsive gatekeepers to attain productive targeted therapy.
What Is Silica? Definition, Main Types, Key Properties and Industrial Uses (2026 Guide)
Fumed Silica Brands Compared: Aerosil, Cab-O-Sil, HDK and Chinese Alternatives
12. Wang Y., Cui Y., Zhao Y., Zhao Q., He B., Zhang Q., Wang S. Effects of surface modification and size on oral drug delivery of mesoporous silica formulation. J. Colloid Interface Sci. 2018;513:736-747. doi: 10.1016/j.jcis.2017.11.065. [ DOI ] [ PubMed ] [ Google Scholar ]
High Purity Quartz Market 2026: Supply, Demand and Price Outlook
Colloidal Silica Slurry: Specifications and Uses in CMP and Precision Polishing
65. Mal A., Prabhuraj R., Malhotra R., Valvi S.K., Ingle A., Srivastava R., De A., Bandyopadhyaya R. pH-responsive sustained delivery of doxorubicin employing aminated and PEGylated mesoporous silica nanoparticles leads to boosted antitumor efficacy in pre-clinical orthotopic breast cancer model. J. Drug Deliv. Sci. Technol. 2022;77:103800. doi: 10.1016/j.jddst.2022.103800. [ DOI ] [ Google Scholar ]
Silica Whiteness: How It Is Measured and Why It Matters for Coatings and Rubber
71. Devangan P., Saini A., Patel D., Kolhe U. Solubility Enhancement of Aripiprazole via Mesoporous Silica: Preparation, Characterization, In vitro Drug Release, and Solubility Determination. J. Pharm. Innov. 2023;18:1316-1327. doi: 10.1007/s12247-023-09722-9. [ DOI ] [ Google Scholar ]
Silica HS Code: Correct Customs Classification for Silica, Quartz and Silica Gel
What is silica (SiO₂)?
top fumed silica manufacturers
98. Vialpando M., Albertini B., Passerini N., Bergers D., Rombaut P., Martens J.A., Mooter G.V.D. Agglomeration of mesoporous silica by melt and steam granulation: Part I: A comparison between disordered and ordered mesoporous silica. J. Pharm. Sci. 2013;102:3966-3977. doi: 10.1002/jps.23700. [ DOI ] [ PubMed ] [ Google Scholar ]
What is the difference between fumed silica and precipitated silica?
hollow silica
33. Zhang J., Dong Y., Liu X., Jin H., Wang S., An N., Wang L. Effective myocardial infarction treatment by targeted accumulation of Sulforaphane using porous magnetic silica nanoparticles. Int. J. Pharm. 2023;645:123389. doi: 10.1016/j.ijpharm.2023.123389. [ DOI ] [ PubMed ] [ Google Scholar ]
What drives silica raw material prices?
silica nanopowder
Nevertheless, mesoporous carriers are frequently associated with poor tabletability because of bad powder flow behavior; thus, direct tableting can only be attained by adding diverse excipients in large quantities [ 95 ]. Such useful excipients include microcrystalline cellulose (filler), lactose monohydrate (filler), PVP (binder), sodium carboxymethylcellulose (disintegrant), croscarmellose sodium (super disintegrant), colloidal silica (anti-adhesion material), magnesium stearate (lubricant), and talc (lubricant) [ 39, 95, 96, 97 ]. However, the drug content in the dosage unit decreases with high amounts of excipients added, so larger tablets must be designed to attain the proper dose [ 95 ]. Another issue is that the greater compression force used during tableting may deform and damage the pore structure of the carrier, which might decrease the expected drug release rate [ 36, 97, 98 ]. When higher compression forces are applied, the pore diameter decreases, which affects both total pore volume and particular surface region, reducing the drug release rate from the carrier [ 97, 98 ]. The use of microcrystalline cellulose may be a solution to this problem, as it deforms plastically under pressure while distributing the energy accumulated in the tablet during compression. Furthermore, croscarmellose sodium may improve the drug release rate [ 97, 98 ]. Granulation of mesoporous material is a proper choice to solve issues related to poor powder rheology.
Cite this article: Silica Raw Materials News. "Silica Price in 2026: Cost by Type, Grade and Key Price Drivers
." Published 2026-11-20 02:59:27. /news/article.html Disclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.